5 Responses to “Is it time to stop surveying Barrett esophagus?”
M. Brian Fennerty, MD
Editor-in-Chief
NEJM Journal Watch Gastroenterology
Biography | Disclosures | Summaries
Learn more about Gut Check on Gastroenterology.
From NEJM: Recently in Gastroenterology- Not Otherwise Specified — Season 3: The Forever Crisis of Primary Care: Misunderstandings — NOS Episode 3.3 October 30, 2025In this episode of NOS, Lisa Rosenbaum and her guests consider the ideals and realities of primary care — and the expectations and misunderstandings that are contributing to its current crisis.
- Case 31-2025: A 56-Year-Old Man with Left Lower Abdominal Pain and Anemia October 30, 2025A 56-year-old man was admitted to the hospital because of left lower abdominal pain and anemia. He had a 1-year history of recurrent diarrhea and an enterocolonic fistula. A diagnosis was made.
- Noninvasive Assessment of Liver Fibrosis October 30, 2025The prognosis of liver disease depends on the extent of fibrosis, which is usually staged with the use of liver biopsy. The limitations of biopsy have led to the development of noninvasive tests, which the authors review.
- Not Otherwise Specified — Season 3: The Forever Crisis of Primary Care: Misunderstandings — NOS Episode 3.3 October 30, 2025
I’m not a doctor but the thought of money being detrimental to the screening for BE is scary….On the other hand, I’m a business owner and understand how business runs!! Mmmmm…interesting discussion. I’ll keep checking in to see how it unfolds.
I, too, am not a doctor, but I have Barrett esophagus. I’ve been having periodic screenings at my gastroenterologist’s suggestion because my father had esophageal cancer. The incidence of cancer in a population may be low, but it needs to be a decision the doctor and patient make together, depending on the patient’s circumstances and medical history.
I think this issue is exemplary of how different points of view can be conflicting. On one side the societal perspective suggests continuing monitoring of BE isn’t worthwhile, the balance being between effectiveness and cost. On the other side the individual perspective affirms: “a low, or very low risk isn’t no risk at all therefore I’d like to continue monitoring even if it produces little good unless the balance between harm and good is decidely shifted”. The sound rationale against PSA screening conjugates the societal perspective: “it is useless” with the individual perspective: “it can do more harm than good”. Until harm from BE monitoring is documented a clearcut position on this issue will be difficult at a clinical level although I feel there is now adequate evidence to reconsidere BE monitoring in the coverage of Health Plans
We should stop surveying Barrett esophagus，but it is not now，why？TO some patient，it saves money，to others，lt means the lost of the chance of early detection for cancer。so，at least by now，we should continue it，but not to all patient。Who should？maybe
patient with high risks into tumor？Now，who is patient with high risks into tumor？it is the key，if we get the key，we solve the problem。
An asymptomatic person does not need a workup but should be endoscoped if a family history of BE exists. A person with esophagitis symptoms would likely be endoscoped; if dysplastic BE is found, that person needs
followup and possible therapy. If non-dysplastic BE is found, we await the next controlled study to determine the appropriate next step. Simple.